fda tirzepatide shortage update today Says Compounded Must Exit the Market FDA Resolves Tirzepatide Shortage: Impact

Were committed to your success every step of the way

There is no need to worry

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

( ) .} , , , ,

The combination is injected directly into a localised pocket of subcutaneous fat using a fine needle or a microcannula